RxDoctor Payments Data

Edward McMillan, MD

Cardiovascular Disease · Charlotte, NCNPI 1831199876

Payments from drug & device makers

$171,270in general payments, 2019–2025

Across 337 payments — averaging $508.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$86K
  • Boehringer Ingelheim International GmbH$50K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$27K
  • Abbott$5K
  • Kestra Medical Technology Services, Inc.$493
  • Boston Scientific$482
  • plus $2K from 21 others

What the payments were for

  • Speaking & faculty fees$4,48045%
  • Travel & lodging$1,00710%
  • Food & beverage$4,46645%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$171,270 in reported general payments places this provider in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$128,716
Medicare patients
1,120
Services billed
1,999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban530$528,511
VyndamaxTafamidis24$524,970
EntrestoSacubitril/Valsartan251$272,752
VyndaqelTafamidis Meglumine11$230,916
Repatha SureclickEvolocumab130$93,992
XareltoRivaroxaban96$92,671
JardianceEmpagliflozin59$49,976
Praluent PenAlirocumab46$31,387
FarxigaDapagliflozin Propanediol36$26,696
Repatha SyringeEvolocumab19$15,564
Ezetimibe301$5,636
Atorvastatin Calcium451$5,093
Rosuvastatin Calcium488$4,706
Metoprolol Succinate331$3,896
Clonidine14$2,835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$86,399$272,752251 claims
Johnson & JohnsonXarelto$260$92,67196 claims
Boehringer IngelheimJardiance$82$49,97659 claims
AstraZenecaFarxiga$204$26,69636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →